Use of protein array to investigate receptor tyrosine kinases activated in gastric cancer

International Journal of Oncology

Volumn 36, Issue 1, 2010, Pages 101-106

  Gong, Jian ^a   Morishita, Asahiro ^a   Kurokohchi, Kazutaka ^a   Tani, Joji ^a   Kato, Kiyohito ^a   Miyoshi, Hisaaki ^a   Inoue, Hideyuki ^a   Kobayashi, Mitsuyoshi ^a   Liu, Shi ^a   Murota, Masayuki ^a   Muramatsu, Akemi ^a   Izuishi, Kunihiko ^a   Suzuki, Yasuyuki ^a   Yoshida, Hirohito ^a   Uchida, Naohito ^a   Deguchi, Kazushi ^a   Iwama, Hisakazu ^a   Ishimaru, Ichiro ^b   Masaki, Tsutomu ^a  

^a KAGAWA UNIVERSITY   (Japan)

^b KAGAWA UNIVERSITY   (Japan)

Author keywords

Gastric cancer; Protein array; Receptor tyrosine kinases

Indexed keywords

ANGIOPOIETIN 1; EPHRIN RECEPTOR A4; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR ALPHA; FIBROBLAST GROWTH FACTOR BETA; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 2 ALPHA; INSULIN RECEPTOR; INTERLEUKIN 8; TRANSFORMING GROWTH FACTOR BETA; TRASTUZUMAB; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG;

ADULT; AGED; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BAGG ALBINO MOUSE; CANCER CELL CULTURE; CANCER GROWTH; CANCER TISSUE; CONTROLLED STUDY; FEMALE; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN MICROARRAY; PROTEIN TARGETING; RECEPTOR UPREGULATION; STOMACH CANCER; STOMACH CARCINOMA; STOMACH MUCOSA; TUMOR XENOGRAFT;

AGED; ANIMALS; CARCINOMA; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE; MICE, NUDE; MIDDLE AGED; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN ARRAY ANALYSIS; RECEPTOR PROTEIN-TYROSINE KINASES; STOMACH NEOPLASMS;

EID: 74549180660     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo-00000480     Document Type: Article

References (37)

1. Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108, 2005.
2. Robinson DR, Wu YM and Lin SF: The protein tyrosine kinase family of the human genome. Oncogene 19: 5548-5557, 2000.
3. Becker JC, Muller-Tidow C, Serve H, Domschke W and Pohle T: Role of receptor tyrosine kinases in gastric cancer: new targets for a selective therapy. World J Gastroenterol 12: 3297-3305, 2006.
4. Hubbard SR and Till JH: Protein tyrosine kinase structure and function. Annu Rev Biochem 69: 373-398, 2000.
5. Tanner M, Hollmen M, Junttila TT, et al: Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 16: 273-278, 2005.
6. Svensson S, Jirström K, Rydén L, Roos G, Emdin S, Ostrowski MC and Landberg G: ERK phosphorylation is linked to VEGFR2 expression and Ets-2 phosphorylation in breast cancer and is associated with tamoxifen treatment resistance and small tumours with good prognosis. Oncogene 24: 4370-4379, 2005.
7. Cao C, Albert JM, Geng L, Ivy PS, Sandler A, Johnson DH and Lu B: Vascular endothelial growth factor tyrosine kinase inhibitor AZD2171 and fractionated radiotherapy in mouse models of lung cancer. Cancer Res 66: 11409-11415, 2006.
8. Masaki T, Tokuda M, Yoshida S, et al: Comparison study of the expressions of myristoylated alanine-rich C kinase substrate in hepatocellular carcinoma, liver cirrhosis, chronic hepatitis, and normal liver. Int J Oncol 26: 661-671, 2005.
9. Yoshida S, Masaki T, Feng H, et al: Enhanced expression of adaptor molecule p46 Shc in nuclei of hepatocellular carcinoma cells: study of LEC rats. Int J Oncol 25: 1089-1096, 2004.
10. Yukimasa S, Masaki T, Yoshida S, et al: Enhanced expression of p46 Shc in the nucleus and p52 Shc in the cytoplasm of human gastric cancer. Int J Oncol 26: 905-911, 2005.
11. D'Incalci M, Colombo T, Ubezio P, et al: The combination of yondelis and cisplatin is synergistic against human tumor xenografts. Eur J Cancer 39: 1920-1926, 2003.
12. Stark A, Hulka BS, Joens S, et al: HER-2/neu amplification in benign breast disease and the risk of subsequent breast cancer. J Clin Oncol 18: 267-274, 2000.
13. Ginestier C, Adélaïde J, Goncalvès A, et al: ERBB2 phosphorylation and trastuzumab sensitivity of breast cancer cell lines. Oncogene 26: 7163-7169, 2007.
14. Hermanova M, Lukas Z, Nenutil R, et al: Amplification and overexpression of HER-2/neu in invasive ductal carcinomas of the pancreas and pancreatic intraepithelial neoplasms and the relationship to the expression of p21 (WAF1/CIP1). Neoplasma 51: 77-83, 2004.
15. Friess T, Scheuer W and Hasmann M: Erlotinib antitumor activity in non-small cell lung cancer models is independent of HER1 and HER2 overexpression. Anticancer Res 26: 3505-3512, 2006.
16. Hatake K, Tokudome N and Ito Y: Tanstuzumab treatment for breast cancer. Intern Med 46: 149-150, 2007.
17. Larbouret C, Robert B, Navarro-Teulon I, et al: In vivo therapeutic synergism of anti-epidermal growth factor receptor and anti-HER2 monoclonal antibodies against pancreatic carcinomas. Clin Cancer Res 13: 3356-3362, 2007.
18. Lara PN Jr, Chee KG, Longmate J, et al: Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma: final results from the California Cancer Consortium Screening and Phase II Trial. Cancer 100: 2125-2131, 2004.
19. Shun CT, Wu MS, Lin JT, et al: Relationship of p53 and c-erbB-2 expression to histopathological features, Helicobacter pylori infection and prognosis in gastric cancer. Hepatogastroenterology 44: 604-609, 1997.
20. Yonemura Y, Ninomiya I, Ohoyama S, et al: Expression of c-erbB-2 oncoprotein in gastric carcinoma. Immunoreactivity for c-erbB-2 protein is an independent indicator of poor short-term prognosis in patients with gastric carcinoma. Cancer 67: 2914-2918, 1991.
21. David L, Seruca R, Nesland JM, et al: C-erbB-2 expression in primary gastric carcinomas and their metastases. Mod Pathol 5: 384-390, 1992.
22. Rebischung C, Barnoud R, Stéfani L, Faucheron JL and Mousseau M: The effectiveness of trastuzumab (Herceptin) combined with chemotherapy for gastric carcinoma with overexpression of the c-erbB-2 protein. Gastric Cancer 8: 206-208, 2005.
23. Inui T, Asakawa A, Morita Y, et al: HER-2 overexpression and targeted treatment by trastuzumab in a very old patient with gastric cancer. J Intern Med 260: 484-487, 2006.
24. Kim SY, Kim HP, Kim YJ, et al: Trastuzumab inhibits the growth of human gastric cancer cell lines with HER2 amplification synergistically with cisplatin. Int J Oncol 32: 89-95, 2008.
25. Hofmann M, Stoss O, Shi D, et al: Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 52: 797-805, 2008.
26. Gravalos C and Jimeno A: HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol 19: 1523-1529, 2008.
27. Marx AH, Tharun L, Muth J, et al: HER-2 amplification is highly homogenous in gastric cancer. Hum Pathol 40: 769-777, 2009.
28. Kim MA, Lee HS, Lee HE, Jeon YK, Yang HK and Kim WH: EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number. Histopathology 52: 738-746, 2008.
29. Shin EY, Lee BH, Yang JH, et al: Up-regulation and coexpression of fibroblast growth factor receptors in human gastric cancer. J Cancer Res Clin Oncol 126: 519-528, 2000.
30. Zhang Y, Zhang J, Lin Y, et al: Role of epithelial cell fibroblast growth factor receptor substrate 2alpha in prostate development, regeneration and tumorigenesis. Development 135: 775-784, 2008.
31. Oki M, Yamamoto H, Taniguchi H, Adachi Y, Imai K and Shinomura Y: Overexpression of the receptor tyrosine kinase EphA4 in human gastric cancers. World J Gastroenterol 14: 5650-5656, 2008.
32. Sliwkowski MX, Lofgren JA, Lewis GD, Hotaling TE, Fendly BM and Fox JA: Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol 26: 60-70, 1999.
33. Cuello M, Ettenberg SA, Clark AS, et al: Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2. Cancer Res 61: 4892-4900, 2001.
34. Vazquez-Martin A, Colomer R and Menendez JA: Protein array technology to detect HER2 (erbB-2)-induced 'cytokine signature' in breast cancer. Eur J Cancer 43: 1117-1124, 2007.
35. Wen XF, Yang G, Mao W, et al: HER2 signaling modulates the equilibrium between pro- and antiangiogenic factors via distinct pathways: implications for HER2-targeted antibody therapy. Oncogene 25: 6986-6996, 2006.
36. Ueda Y, Wang S, Dumont N, Yi JY, Koh Y and Arteaga CL: Overexpression of HER2 (erbB2) in human breast epithelial cells unmasks transforming growth factor beta-induced cell motility. J Biol Chem 279: 24505-24513, 2004.
37. Qiu C, Tarrant MK, Choi SH, et al: Mechanism of activation and inhibition of the HER4/ErbB4 kinase. Structure 16: 460-467, 2008.